RU2010147935A - Терапевтическое восстановление и усиление увлажнения поверхности глаза - Google Patents
Терапевтическое восстановление и усиление увлажнения поверхности глаза Download PDFInfo
- Publication number
- RU2010147935A RU2010147935A RU2010147935/15A RU2010147935A RU2010147935A RU 2010147935 A RU2010147935 A RU 2010147935A RU 2010147935/15 A RU2010147935/15 A RU 2010147935/15A RU 2010147935 A RU2010147935 A RU 2010147935A RU 2010147935 A RU2010147935 A RU 2010147935A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- ophthalmologically acceptable
- therapeutically effective
- effective concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Eyeglasses (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Фармацевтическая композиция, подходящая для местного применения на глазной поверхности, содержащая терапевтически эффективную концентрацию PRG4, суспендированного в офтальмологически приемлемом сбалансированном солевом растворе. ! 2. Фармацевтическая композиция по п.1, содержащая один или более чем один офтальмологически приемлемый агент, выбранный из группы, состоящей из офтальмологически приемлемого успокоительного, офтальмологически приемлемого эксципиента, офтальмологически приемлемого вяжущего, офтальмологически приемлемого сосудосуживающего и офтальмологически приемлемого смягчающего средства. ! 3. Фармацевтическая композиция по п.1, где фармацевтическая композиция содержит PRG4 в терапевтически эффективной концентрации 10-10000 мкг/мл. !4. Фармацевтическая композиция по п.1, где фармацевтическая композиция содержит PRG4 в терапевтически эффективной концентрации 50-500 мкг/мл. ! 5. Фармацевтическая композиция по п.1, также содержащая терапевтически эффективную концентрацию гиалуроната натрия или гиалуроновой кислоты. ! 6. Фармацевтическая композиция по п.5, где фармацевтическая композиция содержит гиалуронат натрия или гиалуроновую кислоту в терапевтически эффективной концентрации 10-100000 мкг/мл. ! 7. Фармацевтическая композиция по п.5, где фармацевтическая композиция содержит гиалуронат натрия или гиалуроновую кислоту в терапевтически эффективной концентрации 500-5000 мкг/мл. ! 8. Фармацевтическая композиция по п.1, также содержащая терапевтически эффективную концентрацию поверхностно-активного фосфолипида, выбранного из группы, состоящей из L-α-дипальмитоилфосфатидилхолина, фосфатидилхолина, фосфат�
Claims (15)
1. Фармацевтическая композиция, подходящая для местного применения на глазной поверхности, содержащая терапевтически эффективную концентрацию PRG4, суспендированного в офтальмологически приемлемом сбалансированном солевом растворе.
2. Фармацевтическая композиция по п.1, содержащая один или более чем один офтальмологически приемлемый агент, выбранный из группы, состоящей из офтальмологически приемлемого успокоительного, офтальмологически приемлемого эксципиента, офтальмологически приемлемого вяжущего, офтальмологически приемлемого сосудосуживающего и офтальмологически приемлемого смягчающего средства.
3. Фармацевтическая композиция по п.1, где фармацевтическая композиция содержит PRG4 в терапевтически эффективной концентрации 10-10000 мкг/мл.
4. Фармацевтическая композиция по п.1, где фармацевтическая композиция содержит PRG4 в терапевтически эффективной концентрации 50-500 мкг/мл.
5. Фармацевтическая композиция по п.1, также содержащая терапевтически эффективную концентрацию гиалуроната натрия или гиалуроновой кислоты.
6. Фармацевтическая композиция по п.5, где фармацевтическая композиция содержит гиалуронат натрия или гиалуроновую кислоту в терапевтически эффективной концентрации 10-100000 мкг/мл.
7. Фармацевтическая композиция по п.5, где фармацевтическая композиция содержит гиалуронат натрия или гиалуроновую кислоту в терапевтически эффективной концентрации 500-5000 мкг/мл.
8. Фармацевтическая композиция по п.1, также содержащая терапевтически эффективную концентрацию поверхностно-активного фосфолипида, выбранного из группы, состоящей из L-α-дипальмитоилфосфатидилхолина, фосфатидилхолина, фосфатидилэтаноламина и сфингомиелина.
9. Фармацевтическая композиция по п.8, где фармацевтическая композиция содержит поверхностно-активный фосфолипид в терапевтически эффективной концентрации 10-10000 мкг/мл.
10. Фармацевтическая композиция по п.1, где офтальмологически приемлемый сбалансированный солевой раствор содержит по меньшей мере три различных электролита, выбранных из группы, состоящей из фосфата натрия, хлорида натрия, хлорида калия, бикарбоната натрия, бикарбоната калия, хлорида кальция, хлорида магния, ацетата натрия, цитрата натрия, соляной кислоты и гидроксида натрия.
11. Фармацевтическая композиция по п.1, где PRG4 является очищенным белком PRG4 природного происхождения или рекомбинантным белком PRG4, включающим его увлажняющий фрагмент, мультимер или гомолог, и имеет среднюю молярную массу менее 400 кДа.
12. Применение фармацевтической композиции по любому из пп.1-11 для производства лекарства для лечения нуждающегося в этом индивидуума от недостаточного увлажнения глаза, состояний, связанных с недостаточным увлажнением глаза или вызывающих недостаточное увлажнение глаза, или симптомов, с ним связанных.
13. Применение фармацевтической композиции по п.12, где нуждающийся в этом индивидуум страдает от недостатка глазной граничной смазки, который связан с болезнью сухого глаза из-за дефицита жидкости или испарения, синдромом Шегрена, сухим кератоконъюнктивитом, андрогенной недостаточностью, заболеванием мейбомиевой железы, заместительной терапией эстрогенами, ношением контактных линз, рефракционной хирургией, аллергией, снижением времени разрушения слезной пленки, нарушением слезной пленки, аллергией, заболеваниями поверхности глаза, повышением уровня протеаз в слезной пленке и на поверхности глаза, хроническим воспалением, гиперосмолярностью, старением и их сочетанием.
14. Применение фармацевтической композиции по п.12, где состояние, которое связано или является причиной недостаточного увлажнения глаза, выбрано из группы, включающей болезнь сухого глаза из-за дефицита жидкости или испарения, синдром Шегрена, сухой кератоконъюнктивит, андрогенную недостаточность, заболевание мейбомиевой железы, заместительную терапию эстрогенами, ношение контактных линз, рефракционную хирургию, аллергию, снижение времени разрушения слезной пленки, нарушение слезной пленки, аллергию, заболевания поверхности глаза, повышение уровня протеаз в слезной пленке и на поверхности глаза, хронические воспаления, гиперосмолярность и старение и их комбинации.
15. Применение фармацевтической композиции по п.12, где фармацевтическую композицию вводят в сочетании с офтальмологически приемлемым составом, включающим один или более чем один офтальмологически приемлемый агент, выбранный из группы, состоящей из офтальмологически приемлемого успокоительного, офтальмологически приемлемого эксципиента, офтальмологически приемлемого вяжущего, офтальмологически приемлемого сосудосуживающего, офтальмологически приемлемого смягчающего средства, офтальмологически приемлемого электролита, офтальмологически приемлемого гиалуроната натрия или гиалуроновой кислоты и офтальмологически приемлемого поверхностно-активного фосфолипида.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5111208P | 2008-05-07 | 2008-05-07 | |
| US61/051,112 | 2008-05-07 | ||
| PCT/US2009/039887 WO2009137217A2 (en) | 2008-05-07 | 2009-04-08 | Therapeutic replenishment and enrichment of ocular surface lubrication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010147935A true RU2010147935A (ru) | 2012-06-20 |
| RU2510274C2 RU2510274C2 (ru) | 2014-03-27 |
Family
ID=41264988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010147935/15A RU2510274C2 (ru) | 2008-05-07 | 2009-04-08 | Терапевтическое восстановление и усиление увлажнения поверхности глаза |
Country Status (16)
| Country | Link |
|---|---|
| US (9) | US9393285B2 (ru) |
| EP (4) | EP2915529B1 (ru) |
| JP (3) | JP5508398B2 (ru) |
| CN (2) | CN105664136A (ru) |
| CA (3) | CA2722913C (ru) |
| CY (2) | CY1119122T1 (ru) |
| DK (3) | DK2285364T3 (ru) |
| ES (3) | ES2530723T3 (ru) |
| HR (3) | HRP20150097T1 (ru) |
| HU (2) | HUE024146T2 (ru) |
| LT (2) | LT2915529T (ru) |
| PL (3) | PL2915529T3 (ru) |
| PT (2) | PT2915529T (ru) |
| RU (1) | RU2510274C2 (ru) |
| SI (3) | SI2285364T1 (ru) |
| WO (3) | WO2009137217A2 (ru) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
| US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
| US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
| US7981146B2 (en) | 2006-05-15 | 2011-07-19 | Tearscience Inc. | Inner eyelid treatment for treating meibomian gland dysfunction |
| WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
| US8083787B2 (en) | 2005-07-18 | 2011-12-27 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction |
| US7981095B2 (en) * | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
| US20090043365A1 (en) * | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
| US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| US8128674B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US8137390B2 (en) | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
| US8007524B2 (en) | 2006-05-15 | 2011-08-30 | Tearscience, Inc. | Heat treatment and heat loss reduction for treating meibomian gland dysfunction |
| US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
| US7981147B2 (en) | 2006-05-15 | 2011-07-19 | Tearscience, Inc. | Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US8128673B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US7976573B2 (en) | 2006-05-15 | 2011-07-12 | Tearscience, Inc. | Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| US8506944B2 (en) * | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| ES2530723T3 (es) | 2008-05-07 | 2015-03-04 | Univ California | Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| US9730865B2 (en) | 2009-05-22 | 2017-08-15 | Lubris, Llc | Application and uses of PRG4 and therapeutic modulation thereof |
| EP2523556A4 (en) * | 2010-01-11 | 2013-08-28 | Gtx Inc | METHOD FOR TREATING MIBROMED DYNAMIC FUNCTION |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| WO2012174123A1 (en) * | 2011-06-13 | 2012-12-20 | Allergan, Inc. | Treatment of psychological trauma |
| BR112013034051A2 (pt) * | 2011-06-29 | 2019-09-24 | Allergan Inc | formulações de macrogol 15 hidroxiestearato |
| US20130029919A1 (en) * | 2011-07-26 | 2013-01-31 | Allergan, Inc. | Two part formulation system for opthalmic delivery |
| SG11201402347YA (en) * | 2011-11-30 | 2014-06-27 | Xigen Inflammation Ltd | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
| ES2942724T3 (es) | 2013-04-30 | 2023-06-06 | Alcon Inc | Sistemas para el tratamiento de enfermedades del ojo |
| US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| CA2903275A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2015060935A1 (en) | 2013-10-22 | 2015-04-30 | Lubris, Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
| US9668916B2 (en) | 2013-11-04 | 2017-06-06 | Vance M. Thompson | Conjunctival cover and methods therefor |
| US20150141328A1 (en) * | 2013-11-18 | 2015-05-21 | The Schepens Eye Research Institute | Stimulation of human meibomian gland function |
| US10500250B2 (en) | 2013-11-26 | 2019-12-10 | Lubris Llc | Compositions and methods for inhibiting intercellular interactions |
| US10940111B2 (en) | 2014-06-15 | 2021-03-09 | Yeda Research And Development Co. Ltd. | Surface treatment by water-soluble polymers and lipids/liposomes |
| IL234929B (en) * | 2014-10-01 | 2021-01-31 | Yeda Res & Dev | Preparations containing liposomes and their use to prevent infections |
| US9395557B2 (en) | 2014-11-12 | 2016-07-19 | Vance M. Thompson | Partial corneal conjunctival contact lens |
| EP3718559A1 (en) * | 2015-01-26 | 2020-10-07 | Lubris LLC | Use of prg4 as an anti-inflammatory agent |
| US9869883B2 (en) | 2015-03-11 | 2018-01-16 | Vance M. Thompson | Tear shaping for refractive correction |
| TW201642868A (zh) * | 2015-04-03 | 2016-12-16 | 參天製藥股份有限公司 | 以諾龍或其酯、美替諾龍或其酯作爲有效成分之乾眼症治療劑 |
| SI3300482T1 (sl) * | 2015-05-19 | 2021-11-30 | Lubris Llc | Uporaba prg4 za izboljšanje dinamične ostrine vide in aberacij višjega reda |
| JP6718608B2 (ja) * | 2016-05-25 | 2020-07-08 | 国立大学法人愛媛大学 | 眼表面・眼瞼摩擦係数測定装置および眼表面・眼瞼摩擦係数評価方法 |
| US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
| US10353220B2 (en) | 2016-10-17 | 2019-07-16 | Vance M. Thompson | Tear shaping for refractive correction |
| US10678067B2 (en) | 2018-04-06 | 2020-06-09 | Vance M. Thompson | Tear shaping for refractive correction |
| CN112351792A (zh) * | 2018-06-21 | 2021-02-09 | 卢布里斯有限责任公司 | 用于创伤愈合的润滑素 |
| US20220008518A1 (en) * | 2018-11-08 | 2022-01-13 | The Schepens Eye Research Institute, Inc. | Therapeutic approaches for tissue reconstruction and wound healing treatment |
| US20220273844A1 (en) * | 2019-07-26 | 2022-09-01 | Pandorum Technologies Private Limited | Bio-ink formulations, bio-printed corneal lenticule, and applications thereof |
| WO2021067823A2 (en) * | 2019-10-05 | 2021-04-08 | The Schepens Eye Research Institute, Inc. | A new treatment for meibomian gland dysfunction |
| US11609438B2 (en) * | 2019-10-31 | 2023-03-21 | Menicon Singapore Pte Ltd. | Ocular lens with friction control structures |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550022A (en) * | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
| SE8501723L (sv) | 1985-04-09 | 1986-10-10 | Pharmacia Ab | Preparation att anvendas vid behandling av ledinflammation |
| US4964206A (en) * | 1988-03-15 | 1990-10-23 | Minnesota Mining And Manufacturing Company | Intraocular lens anchoring filament to lens element fixation method |
| US4964205A (en) * | 1988-06-13 | 1990-10-23 | Rampart Packaging Inc. | Method for making screw cap jar |
| US6433142B1 (en) | 1989-08-08 | 2002-08-13 | Genetics Institute, Llc | Megakaryocyte stimulating factors |
| US5326558A (en) | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
| RU2033165C1 (ru) | 1989-10-13 | 1995-04-20 | Межотраслевой научно-технический комплекс "Микрохирургия глаза" | Способ получения пластичного материала из коллагена |
| US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
| AU674681B2 (en) | 1992-04-21 | 1997-01-09 | Schepens Eye Research Institute, Inc., The | Ocular androgen therapy in Sjogren's syndrome |
| US5688765A (en) | 1992-04-21 | 1997-11-18 | The Schepens Eye Research Institute, Inc. | Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β |
| IL106922A (en) * | 1992-09-14 | 1998-08-16 | Novartis Ag | Complex materials with one or more wettable surfaces and a process for their preparation |
| US5351100A (en) * | 1992-12-09 | 1994-09-27 | Bmc Industries, Inc. | Glass multifocal ophthalmic lens with polarizing element and method of making |
| DE69434617D1 (de) | 1993-11-19 | 2006-04-06 | Univ Sydney | Verfahren zur prophylaxe oder kontrolle des katarakts |
| US5515590A (en) * | 1994-07-19 | 1996-05-14 | University Of Kentucky Research Foundation | Method for reducing the generation of wear particulates from an implant |
| US5518732A (en) * | 1995-02-14 | 1996-05-21 | Chiron Vision, Inc. | Bio-erodible ophthalmic shield |
| DE69629230D1 (de) | 1995-03-24 | 2003-09-04 | Ocular Res Of Bonton Inc | Hydrogellinse mit Lipid-Vorbeschichtigung |
| RU2207885C2 (ru) * | 1995-08-30 | 2003-07-10 | Фармация Аб | Способ подачи небольшого объема лечебного раствора к целевому месту |
| US6689748B1 (en) * | 1998-04-08 | 2004-02-10 | Theoharis C. Theoharides | Method of treating mast cell activation-induced diseases with a proteoglycan |
| WO2000027421A2 (en) * | 1998-11-06 | 2000-05-18 | The Schepens Eye Research Institute, Inc. | LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE |
| AU774977B2 (en) * | 1998-11-10 | 2004-07-15 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid gel, process for the preparation thereof and medical materials containing the same |
| US6743774B1 (en) | 1999-04-23 | 2004-06-01 | Rhode Island Hospital | Tribonectins |
| US6960562B2 (en) | 1999-04-23 | 2005-11-01 | Rhode Island Hospital, A Lifespan Partner | Tribonectin polypeptides and uses thereof |
| CN1259343C (zh) | 2000-02-03 | 2006-06-14 | 电气化学工业株式会社 | 透明质酸凝胶、其制造方法以及含有它的医用材料 |
| US20030021854A1 (en) | 2001-04-23 | 2003-01-30 | Burrell Robert Edward | Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| US6919321B2 (en) * | 2000-12-20 | 2005-07-19 | Alcon, Inc. | Ophthalmic lubricating solution adapted for use in lasik surgery |
| BR0116353A (pt) * | 2000-12-20 | 2005-04-05 | Alcon Inc | Solução de irrigação intraocular dotada de caracterìsticas de fluxo aperfeiçoadas |
| US6815074B2 (en) | 2001-05-30 | 2004-11-09 | Novartis Ag | Polymeric materials for making contact lenses |
| CN1980582B (zh) | 2001-08-17 | 2010-12-22 | 美你康株式会社 | 用于用后即弃式软隐形眼镜的包装 |
| US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| TWI255224B (en) | 2002-01-09 | 2006-05-21 | Novartis Ag | Polymeric articles having a lubricious coating and method for making the same |
| AR038926A1 (es) | 2002-03-13 | 2005-02-02 | Novartis Ag | Materiales con contenido de multiples capas de vesiculas |
| SE0201479D0 (sv) | 2002-05-16 | 2002-05-16 | Pharmacia Groningen Bv | Kit and method in eye surgery |
| US20050196370A1 (en) | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| US20050074497A1 (en) | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| KR20060095863A (ko) | 2003-08-06 | 2006-09-04 | 니르말 뮬레 | 수용성 의약을 함유하는 제약학적 조성물 |
| MXPA06001658A (es) * | 2003-08-14 | 2006-04-28 | Wyeth Corp | Moleculas de lubricina recombinantes y usos de las mismas. |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| WO2005027933A1 (en) | 2003-09-23 | 2005-03-31 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Unsaturated phosphatidylcholines and uses thereof |
| US20070275032A1 (en) * | 2004-03-05 | 2007-11-29 | Synthes (U.S.A.) | Use Of A Mixture For The Production Of An Agent For Treating Defective Or Degenerated Cartilage In The Production Of Natural Cartilage Replacement In Vitro |
| US20090060933A1 (en) | 2004-06-14 | 2009-03-05 | Estell David A | Proteases producing an altered immunogenic response and methods of making and using the same |
| US20050287223A1 (en) | 2004-06-23 | 2005-12-29 | Peyman Gholam A | Use of amniotic membrane as biocompatible devices |
| EP1768687A2 (en) * | 2004-06-29 | 2007-04-04 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
| JP2008507553A (ja) * | 2004-07-23 | 2008-03-13 | ミューコサル セラピューティクス リミテッド ライアビリディ カンパニー | 粘性補給のための組成物および方法 |
| US7662509B2 (en) * | 2004-10-29 | 2010-02-16 | Medtronic, Inc. | Lithium-ion battery |
| US20060210645A1 (en) * | 2005-03-02 | 2006-09-21 | Du Mee Charles P | Pharmaceutically acceptable carrier for ophthalmic compositions |
| ES2614080T3 (es) | 2005-05-17 | 2017-05-29 | Sarcode Bioscience Inc. | Composiciones y métodos para el tratamiento de trastornos oculares |
| US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
| JP5549045B2 (ja) * | 2006-01-13 | 2014-07-16 | 大正製薬株式会社 | 蒸発亢進型ドライアイの予防又は改善用水性点眼剤 |
| US20080094573A1 (en) | 2006-04-04 | 2008-04-24 | Vermette Patrick | Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof |
| US9539202B2 (en) * | 2006-04-28 | 2017-01-10 | Universidad Complutense De Madrid | Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics |
| US20070264226A1 (en) | 2006-05-10 | 2007-11-15 | Karagoezian Hampar L | Synergistically enhanced disinfecting solutions |
| PT2054049E (pt) * | 2006-08-24 | 2016-06-02 | Univ Tennessee Res Found | Acilanilidas substituídas e métodos de utilização das mesmas |
| US20080097606A1 (en) | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| US20080197324A1 (en) | 2007-02-20 | 2008-08-21 | Fang Zhao | Ophthalmic composition containing a polyol-acid copolymer |
| US20090068247A1 (en) | 2007-09-12 | 2009-03-12 | Mucosal Therapeutics | Biocompatible devices coated with a tribonectin and methods for their production |
| BRPI0821158A2 (pt) | 2007-12-20 | 2015-06-16 | Novartis Ag | Método para fazer lentes de contato |
| US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
| ES2530723T3 (es) | 2008-05-07 | 2015-03-04 | Univ California | Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular |
-
2009
- 2009-04-08 ES ES09743204T patent/ES2530723T3/es active Active
- 2009-04-08 DK DK09743204.1T patent/DK2285364T3/en active
- 2009-04-08 PL PL15151634T patent/PL2915529T3/pl unknown
- 2009-04-08 CN CN201610003437.XA patent/CN105664136A/zh active Pending
- 2009-04-08 DK DK15151634.1T patent/DK2915529T3/en active
- 2009-04-08 PT PT151516341T patent/PT2915529T/pt unknown
- 2009-04-08 JP JP2011508534A patent/JP5508398B2/ja active Active
- 2009-04-08 CN CN200980126381.5A patent/CN102164593B/zh active Active
- 2009-04-08 SI SI200931129T patent/SI2285364T1/sl unknown
- 2009-04-08 CA CA2722913A patent/CA2722913C/en active Active
- 2009-04-08 LT LTEP15151634.1T patent/LT2915529T/lt unknown
- 2009-04-08 RU RU2010147935/15A patent/RU2510274C2/ru active
- 2009-04-08 ES ES15151634.1T patent/ES2633792T3/es active Active
- 2009-04-08 EP EP15151634.1A patent/EP2915529B1/en active Active
- 2009-04-08 PL PL09743204T patent/PL2285364T3/pl unknown
- 2009-04-08 EP EP09743204.1A patent/EP2285364B1/en active Active
- 2009-04-08 SI SI200931699T patent/SI2915529T1/sl unknown
- 2009-04-08 PT PT97432041T patent/PT2285364E/pt unknown
- 2009-04-08 HU HUE09743204A patent/HUE024146T2/en unknown
- 2009-04-08 WO PCT/US2009/039887 patent/WO2009137217A2/en active Application Filing
- 2009-05-06 ES ES09743588T patent/ES2748139T3/es active Active
- 2009-05-06 CA CA2722944A patent/CA2722944A1/en not_active Abandoned
- 2009-05-06 PL PL09743588T patent/PL2276496T3/pl unknown
- 2009-05-06 JP JP2011508633A patent/JP5439652B2/ja active Active
- 2009-05-06 CA CA2723144A patent/CA2723144C/en active Active
- 2009-05-06 WO PCT/US2009/043018 patent/WO2009137603A1/en active Application Filing
- 2009-05-06 LT LT09743588T patent/LT2276496T/lt unknown
- 2009-05-06 EP EP09743588.7A patent/EP2276496B1/en active Active
- 2009-05-06 HU HUE09743588A patent/HUE045686T2/hu unknown
- 2009-05-06 DK DK09743588.7T patent/DK2276496T3/da active
- 2009-05-06 EP EP09743589.5A patent/EP2276497B1/en active Active
- 2009-05-06 JP JP2011508634A patent/JP5474054B2/ja active Active
- 2009-05-06 SI SI200932001T patent/SI2276496T1/sl unknown
- 2009-05-06 WO PCT/US2009/043015 patent/WO2009137602A1/en active Application Filing
-
2010
- 2010-11-05 US US12/940,370 patent/US9393285B2/en active Active
- 2010-11-05 US US12/940,454 patent/US8563028B2/en active Active
- 2010-11-05 US US12/940,425 patent/US9138457B2/en active Active
-
2013
- 2013-09-20 US US14/032,233 patent/US8945604B2/en active Active
-
2014
- 2014-05-08 US US14/272,634 patent/US9248161B2/en active Active
-
2015
- 2015-01-26 HR HRP20150097AT patent/HRP20150097T1/hr unknown
- 2015-08-20 US US14/831,317 patent/US9421241B2/en active Active
- 2015-12-18 US US14/974,055 patent/US9585936B2/en active Active
-
2016
- 2016-04-06 US US15/091,665 patent/US9730978B2/en active Active
-
2017
- 2017-07-10 US US15/645,561 patent/US20180028598A1/en not_active Abandoned
- 2017-07-13 HR HRP20171079TT patent/HRP20171079T1/hr unknown
- 2017-07-14 CY CY20171100751T patent/CY1119122T1/el unknown
-
2019
- 2019-09-25 HR HRP20191732 patent/HRP20191732T1/hr unknown
- 2019-10-03 CY CY20191101037T patent/CY1122638T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010147935A (ru) | Терапевтическое восстановление и усиление увлажнения поверхности глаза | |
| JP6666487B2 (ja) | ドライアイ治療用点眼剤 | |
| ES2324118T3 (es) | Composicion farmaceutica sin dexpantenol, iones calcio y fosfato asi como uso de quelantes de calcio y regulador de la viscosidad oftalmologicamente compatible. | |
| JP3058920B2 (ja) | アルブミンを有効成分とする医薬組成物 | |
| ES2813649T3 (es) | Composición farmacéutica administrable por vía oral para la prevención o el tratamiento del síndrome del ojo seco, que comprende rebamipida o un profármaco de la misma | |
| AU2006260184B2 (en) | Prophylactic or therapeutic agent for corneal/conjunctival disease | |
| EP2224949A1 (en) | Use of urokinase type plasminogen activator inhibitors for the treatment of corneal disorders | |
| JP4987078B2 (ja) | 眼科用組成物 | |
| ES2747501T3 (es) | Composición oftálmica para uso en el tratamiento de trastornos oculares relacionados con alteraciones de la superficie córneo-conjuntival | |
| Liang et al. | Salidroside alleviates oxidative stress in dry eye disease by activating autophagy through AMPK-Sirt1 pathway | |
| US7758883B2 (en) | Three layer artificial tear formulation | |
| TW201350109A (zh) | 用於降低眼部不適的方法及組成物 | |
| JP7404658B2 (ja) | 涙液層安定化剤及びマイバム分泌促進剤 | |
| TW201828954A (zh) | 用於預防或治療乾眼症之含硫糖肽或其藥學上可接受鹽類之藥用組合物 | |
| Nelson et al. | Evaluation of a physiological tear substitute in patients with keratoconjunctivitis sicca | |
| Park et al. | Polygonum cuspidatum stem extract (PSE) ameliorates dry eye disease by inhibiting inflammation and apoptosis | |
| RU2464985C1 (ru) | Композиция для комплексного лечения больных с первичной открытоугольной глаукомой и заболеваниями глазной поверхности | |
| US10456374B2 (en) | Pyrrolidone carboxylic acid (PCA) for ophthalmic use | |
| TW201625277A (zh) | 角結膜障礙治療劑 | |
| Wagh et al. | Drug delivery and pharmacotherapy for dry eye disease | |
| RU2706703C1 (ru) | Раствор увлажняющий офтальмологический | |
| RU2517033C1 (ru) | Композиция для комплексного лечения больных с первичной открытоугольной глаукомой и заболеваниями глазной поверхности | |
| ES2875354T3 (es) | Composiciones farmacéuticas | |
| CN111632128A (zh) | 短链胜肽组合物在预防或治疗干眼症的应用 | |
| JP2018035075A (ja) | ドライアイ治療剤 |